Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Combined Training (Strength and Endurance) and the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men

18 juni 2026 uppdaterad av: Arya Habibi

Effect of Upper Body and Lower Body Combined Training (Strength and Endurance) on the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men

This randomized controlled trial investigated the effects of upper body-based and lower body-based combined training on serum levels of myostatin (MSTN) and hormone-sensitive lipase (HSL) in overweight and obese men. Myostatin is a myokine involved in the regulation of skeletal muscle growth and adipose tissue metabolism, while HSL is a key enzyme involved in lipolysis and fat mobilization.

Thirty-six overweight and obese men were assigned to either an upper body combined training group, a lower body combined training group, or a non-exercising control group. The intervention consisted of 10 weeks of combined resistance and aerobic training performed three times per week. Serum levels of MSTN and HSL were measured before and after the intervention to determine whether upper body-focused and lower body-focused combined training produce different effects on markers associated with muscle growth and lipid metabolism.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

36

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Tehran Province
      • Tehran, Tehran Province, Iran
        • Faculty of Sports and Health Sciences of the University of Tehran

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

  • Male participants aged 20 to 45 years.
  • Body mass index (BMI) ≥25 kg/m².
  • Overweight or obese status.
  • No participation in regular resistance or aerobic exercise during the previous 6 months.
  • Willingness to participate and provide written informed consent.

Exclusion Criteria:

  • Presence of metabolic diseases, including diabetes mellitus.
  • Presence of cardiovascular or respiratory diseases.
  • Musculoskeletal or joint injuries that could interfere with exercise participation.
  • Use of anti-obesity medications.
  • Use of anabolic steroids, sports supplements, or fat-burning supplements.
  • Regular alcohol consumption or tobacco use.
  • Absence from more than two training sessions during the intervention period.
  • Withdrawal of consent or unwillingness to continue participation.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Upper Body Combined Training
Participants completed a 10-week upper body-focused combined training program three times per week. Each session consisted of upper body resistance exercises followed by aerobic exercise performed on a hand ergometer. Resistance training included chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal exercises.
Participants completed a 10-week upper body-focused combined training program performed three times per week. Each session included six upper body resistance exercises (chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal machine exercises) followed by aerobic exercise on a hand ergometer. Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set. Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week. Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training.
Andra namn:
  • Upper Body Resistance and Aerobic Training
Experimentell: Lower Body Combined Training
Participants completed a 10-week lower body-focused combined training program three times per week. Each session consisted of lower body resistance exercises followed by aerobic exercise performed on a leg ergometer. Resistance training included leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises.
Participants completed a 10-week lower body-focused combined training program performed three times per week. Each session included six lower body resistance exercises (leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises) followed by aerobic exercise on a leg ergometer. Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set. Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week. Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training.
Andra namn:
  • Lower Body Resistance and Aerobic Training
Inget ingripande: Control
Participants in the control group did not participate in the exercise intervention and were instructed to maintain their usual daily activities throughout the 10-week study period.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in serum myostatin (MSTN) concentration
Tidsram: Baseline and 10 weeks
Serum myostatin concentration measured by enzyme-linked immunosorbent assay (ELISA). The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
Baseline and 10 weeks
Change in serum hormone-sensitive lipase (HSL) concentration
Tidsram: Baseline and 10 weeks
Serum hormone-sensitive lipase concentration measured by enzyme-linked immunosorbent assay (ELISA). The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
Baseline and 10 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 maj 2024

Primärt slutförande (Faktisk)

1 maj 2024

Avslutad studie (Faktisk)

15 december 2024

Studieregistreringsdatum

Först inskickad

14 juni 2026

Först inskickad som uppfyllde QC-kriterierna

14 juni 2026

Första postat (Faktisk)

18 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data (IPD) will not be made publicly available. The study was not originally designed with a formal data-sharing plan, and participant-level data contain information that could potentially compromise participant confidentiality.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera